Bioresorbable scaffolds for the treatment of in-stent restenosis

Heart and Vessels

Volumn 30, Issue 2, 2015, Pages 265-269

  Dörr, Oliver ^a   Liebetrau, Christoph ^b   Wiebe, Jens ^a   Hecker, Franziska ^a   Rixe, Johannes ^a   Möllmann, Helge ^b   Hamm, Christian ^a,b   Nef, Holger ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Kerckhoff Heart and Thorax Center ^*  (Germany)

Author keywords

Bioresorbable coronary scaffolds; In stent restenosis

Indexed keywords

ADVERSE EFFECTS; AGED; ANGIOCARDIOGRAPHY; BIODEGRADABLE IMPLANT; CASE REPORT; CORONARY RESTENOSIS; DEVICES; HUMAN; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS; STENT; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; STENTS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84952308875     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0464-5     Document Type: Article

References (7)

1. Stone G, Moses J, Ellis S, Schofer J, Dawkins K, Morice M, Colombo A, Schampert E, Grube E, Kirtane A, Cutlip D, Fahy M, Pocock S, Mehran R, Leon M (2007) Safety and efficacy of sirolimus and paclitaxel eluting coronary stents. N Engl J Med 356:998–1008
2. Morice M, Serruys P, Sousa J, Fajadet J, Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R (2002) A randomised comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780
3. ® stent due to hypersensitivity reaction confirmed by pathohistological findings. Heart Vessels 27(1):110–113
4. Ikuta S, Kobuke K, Iwanaga Y, Nakauchi Y, Yamaji K, Miyazaki S (2013) Difference in neointimal coverage at chronic stage between bare metal stent and sirolimus-eluting stent evaluated at stent-strut level by optical coherence tomography. Heart Vessels. doi:10.1007/s00380-013-0376-4
5. Barbash IM, Waksman R (2011) Current status, challenges and future directions of drug-eluting balloons. Future Cardiol 7:765–774
6. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW (2013) Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 99(2):98–105
7. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D (2009) A bioabsorbable everolimus-eluting coronary stentsystem (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373:897–910